Hospital
Indiana University Health Frankfort INC
Indiana University Health Frankfort INC was paid $6.21M by Medicaid between Jan 2018 and Nov 2024, across 56 billing codes. Its largest line is 99283, emergency room visit (moderate) — 42% of everything it billed.
33Billing provider infoINDIANA UNIVERSITY HEALTH FRANKFORT INC
FRANKFORT, IN 46041
FRANKFORT, IN 46041
33aNPI1346774270assigned 04/18/2017
33bProvider typeCritical Access Hospital
28Total paid$6.21M
24GClaims95,838
24DCodes billed56
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Indiana
Rank by total paid#7 of 26
Median peer was paid$4.16M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,782 | $484K | |
| 2019 | 6,683 | $345K | |
| 2020 | 7,796 | $364K | |
| 2021 | 14,703 | $940K | |
| 2022 | 22,810 | $1.52M | |
| 2023 | 18,041 | $1.45M | |
| 2024incomplete | 11,023 | $1.11M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 42% | 14,508 | 12,846 | $2.61M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 6,783 | 5,807 | $1.08M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 5,753 | 4,664 | $728K |
| 71045 | Radiologic examination, chest; single view | 7.1% | 3,330 | 2,726 | $439K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.8% | 4,540 | 3,713 | $234K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.9% | 3,059 | 2,492 | $178K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.2% | 1,742 | 1,526 | $138K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 2,778 | 2,250 | $105K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.7% | 602 | 192 | $104K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.1% | 1,689 | 1,389 | $68K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 1,489 | 1,279 | $64K |
| 80053 | Comprehensive metabolic panel | <1% | 9,082 | 7,563 | $58K |
44 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,765 | $51K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 227 | $50K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 471 | $38K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 967 | $36K |
| 87503 | <1% | 1,359 | $33K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,603 | $32K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 70 | $29K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 246 | $27K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 800 | $23K |
| 84484 | <1% | 3,108 | $19K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 564 | $11K |
| 83690 | <1% | 1,967 | $8K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 127 | $8K |
| 81025 | <1% | 1,150 | $8K | |
| 83735 | <1% | 1,870 | $7K | |
| 81001 | <1% | 2,334 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,466 | $5K |
| 83605 | <1% | 494 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 69 | $2K |
| 83880 | <1% | 134 | $2K | |
| 81003 | <1% | 1,277 | $2K | |
| 87400 | <1% | 175 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 161 | $1K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 15 | $1K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 432 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 307 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 136 | $927.75 |
| 87040 | <1% | 164 | $842.10 | |
| 82550 | <1% | 131 | $416.26 | |
| 82553 | <1% | 115 | $380.79 | |
| 80051 | <1% | 81 | $295.17 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 77 | $280.15 |
| 82565 | <1% | 98 | $270.53 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 28 | $252.00 |
| 84520 | <1% | 98 | $208.51 | |
| 82947 | <1% | 98 | $207.43 | |
| 87420 | <1% | 14 | $194.74 | |
| 85610 | <1% | 47 | $105.30 | |
| 80076 | <1% | 31 | $69.71 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 21 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 72 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 65 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 33 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVASQUEZ, ART (CFO)